Journal of Endocrinological Investigation

, Volume 27, Issue 3, pp 221–229 | Cite as

Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon?

Article

Abstract

The extra ocular (eye) muscles are one of the principal tissues involved in the autoimmune-mediated inflammation of Graves’ ophthalmopathy (GO). Several eye muscle proteins are targeted by autoantibodies or sensitized T lymphocytes, or both, and include: G2s, which is now identified as the terminal 141 amino acids of the winged-helix transcription factor FOXP1, the flavoprotein (Fp) subunit of the mitochondrial enzyme succinate dehydrogenase, the so-called “64kDa protein”, a non-tissue specific membrane protein called 1D and the calcium binding protein calsequestrin. Of these, antibodies against G2s and Fp are the most sensitive markers of eye muscle damage in patients with thyroid autoimmunity even though neither antigen is specific to eye muscle and neither antibody is specific to GO. However, the recent finding that the calsequestrin gene is 4.7 times more expressed in eye muscles than other skeletal muscles suggests that we should reconsider the possible role of anti-calsequestrin autoantibodies in ophthalmopathy. GO may comprise two main subtypes with different pathogenetic mechanisms, namely ocular myopathy in which eye muscle inflammation predominates and congestive ophthalmopathy where inflammatory changes occur in the periorbital connective tissues in the absence of eye muscle dysfunction. Anti-G2s and anti-Fp antibodies are closely associated with the ocular myopathy subtype of GO while antibodies targeting type XIII collagen, the only member of the collagen family to have a transmembrane domain, are closely linked to congestive ophthalmopathy. Since both G2s and Fp are intracellular antigens it is unlikely that either antibody causes eye muscle fiber damage in GO, although a role in the later stages of the disease when the fiber has released its cellular contents has not been excluded. Eye muscle antibodies that are cytotoxic to eye muscle cells in antibody-dependent cell-mediated cytotoxicity (ADCC) are more likely to play a role in eye muscle fiber damage since they target a putative eye muscle cell membrane antigen, the identity of which is currently being investigated. While anti-G2s and anti-Fp antibodies are probably secondary to an underlying reaction, such as cytotoxic T lymphocyte targeting of an eye muscle membrane antigen that has yet to be identified, they are reliable markers of immunologically mediated eye muscle fiber damage in patients with Graves’ hyperthyroidism. In conclusion, while a pathogenic role for eye muscle antibodies has not been excluded, they are most likely secondary to cytotoxic T cell reactions in GO and, as such, good markers of this autoimmune disease.

Key-words

Eye muscle antibody Graves’ disease ophthalmopathy G2s flavoprotein autoimmunity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wall JR. Graves’ disease is a multi-system autoimmune disorder in which extra ocular muscle damage and connective tissue inflammation are variable features. Thyroid 2002, 12: 35–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Burch HB, Gorman CA, Bahn RS, Garrity JA. Ophthalmopathy. In: Braverman LE, Utiger RD eds. Werner and Ingbar’s the thyroid. 8th ed. Philadelphia: Lippincott Williams and Wilkins. 2000, 531.Google Scholar
  3. 3.
    Solovyeva TP. Endocrine ophthalmopathies. Problems of rational classification. Orbit 1989, 3: 193–8CrossRefGoogle Scholar
  4. 4.
    Kasper M, Archibald C, De Bellis AM, et al. Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy. Proc Intl Symp on Thyroid Associated Ophthalmopathy, Kyoto, Japan, October 2000. Thyroid 2000, 12(Suppl.): 187–91.Google Scholar
  5. 5.
    Miller A, Arthurs B, Boucher A, et al. Significance of antibodies reactive with a 64-kDa eye muscle membrane antigen in patients with thyroid autoimmunity. Thyroid 1992, 2: 197–202.PubMedCrossRefGoogle Scholar
  6. 6.
    Wall JR, Salvi M, Bernard NF, Boucher A, Haegert D. Thyroid-associated ophthalmopathy—a model for the association of organ-specific autoimmune disorders. Immunol Today 1991, 12: 150–3.PubMedCrossRefGoogle Scholar
  7. 7.
    Wall JR, Bernard N, Boucher A, et al. Pathogenesis of thyroid-associated ophthalmopathy: an autoimmune disorder of the eye muscle associated with Graves’ hyperthyroidism and Hashimoto’s thyroiditis. Clin Immunol Immunopathol 1993, 68: 1–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Weightman D, Kendall-Taylor P. Cross-reaction of eye muscle antibodies with thyroid tissue in thyroid- associated ophthalmopathy. J Endocrinol 1989, 122: 201–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Yamada M, Li AW, Wall JR. Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management. Crit Rev Clin Lab Sci 2000, 37: 523–49.PubMedCrossRefGoogle Scholar
  10. 10.
    Bednarczuk T, Stolarski C, Pawlik E, et al. Autoantibodies reactive with extracellular matrix proteins in patients with thyroid-associated ophthalmopathy. Thyroid 1999, 9: 289–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Wall JR, Blanchard ME, West K, Yamada M, Li AW, Pihlajaniemi T. Autoantibodies against the plasma membrane protein type XIII collagen are new markers of congestive ophthalmopathy. Thyroid 1999 9(Suppl.): 50 (abstract).Google Scholar
  12. 12.
    Hagg P, Rehn M, Huhtala P, Vaisanen T, Tamminen M, Pihlajaniemi T. Type XIII collagen is identified as a plasma membrane protein. J Biol Chem 1998, 273: 15590–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab 1998, 83: 998–1002.PubMedGoogle Scholar
  14. 14.
    Ludgate M, Crisp M, Lane C, et al. The thyrotropin receptor in thyroid eye disease. Thyroid 1998, 8: 411–3PubMedCrossRefGoogle Scholar
  15. 15.
    Noh JY, Hamada N, Inoue Y, Ito K. Thyroid-stimulating antibody is related to Graves’ ophthalmopathy, but Thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves’ disease. Thyroid 2001, 10: 809–13.CrossRefGoogle Scholar
  16. 16.
    Busuttil BE, Frauman AG. Extrathyroidal manifestations of Graves’ disease: the thyrotropin receptor is expressed in extraocular, but not cardiac, muscle tissues. J Clin Endocrinol Metab 2001, 86: 2315–9.PubMedGoogle Scholar
  17. 17.
    Kiljanski JI, Nebes V, Wall JR. The ocular muscle cell is a target of the immune system in endocrine ophthalmopathy. Int Arch Allergy Immunol 1995, 106: 204–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Weetman AP. Graves’ disease. N Engl J Med 2000, 343: 1236–48.PubMedCrossRefGoogle Scholar
  19. 19.
    Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves’ disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995, 80: 28830–8.Google Scholar
  20. 20.
    Tallstedt L, Norberg R. Immunohistochemical staining of normal and Graves’ extraocular muscle. Invest Ophthalmol Vis Sci 1988, 29: 175–84.PubMedGoogle Scholar
  21. 21.
    Kahaly G, Hansen C, Felke B, Dienes HP. Immunohistochemical staining of retrobulbar adipose tissue in Graves’ ophthalmopathy. Clin Immunol Immunopathol 1994, 73: 53–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Van der Gaag R, Schmidt ED, Koornneef L. Retrobulbar histology and immunohistochemistry in endocrine ophthalmopathy. Dev Ophthalmol 1993, 25: 1–10.PubMedGoogle Scholar
  23. 23.
    Wall JR, Bernard N, Zhang ZG, et al. Pathogenesis of thyroid-associated ophthalmopathy; an autoimmune disorder of the eye muscle associated with Graves’ hyperthyroidism and Hashimoto’s thyroiditis. Clin Immunol Immunopathol 1993, 68: 1–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Kodama K, Sikorska H, Bandy-Dafoe P, Bayly R, Wall JR. Demonstration of circulating autoantibody against a soluble eye muscle antigen in Graves’ ophthalmopathy. Lancet 1982, 2: 1353–6PubMedCrossRefGoogle Scholar
  25. 25.
    Atkinson S, Holcombe M, Kendall-Taylor P. Ophthalmopathic immunoglobulin in patients with Graves’ ophthalmopathy. Lancet 1984, 2: 374–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Faryna M, Nauman J, Gardas A. Measurement of autoantibodies against human eye muscle plasma membranes in Graves’ ophthalmopathy. Br Med J 1985, 290: 191–2.CrossRefGoogle Scholar
  27. 27.
    Kahaly G, Moncayo R, Bemetz U, Krause U, Beyer J, Pfeiffer EF. Eye muscle antibodies in endocrine exophthalmos. Clinical and serological observations. Horm Metab Res 1989, 21: 137–41.PubMedCrossRefGoogle Scholar
  28. 28.
    Wu YJ, Clarke EM, Shepherd P. Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves’ ophthalmopathy and other thyroid and nonthyroid diseases. Thyroid 1998, 8: 167–74.PubMedCrossRefGoogle Scholar
  29. 29.
    Chang TC, Chang TJ, Huang YS, Huang KM, Su RJ, Kao SC. Identification of autoantigen recognized by autoimmune ophthalmopathy sera with immunoblotting correlated with orbital computed tomography. Clin Immunol Immunopathol 1992, 65: 161–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Wall JR. Nature and significance of eye muscle autoantigens in endocrine ophthalmopathy. Dev Ophthalmol 1993, 25: 77–85.PubMedGoogle Scholar
  31. 31.
    Salvi M, Miller A, Wall JR. Human orbital tissue and thyroid membranes express a 64 kDa protein which is recognized by autoantibodies in the serum of patients with thyroid-associated ophthalmopathy. FEBS Lett 1988, 232: 135–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Gunji K, De Bellis A, Li AW, et al. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 2000, 85: 1641–7.PubMedGoogle Scholar
  33. 33.
    Salvi M, Bernard N, Miller A, Zhang ZG, Gardini E, Wall JR. Prevalence of antibodies reactive with a 64 kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy. Thyroid 1991, 1: 207–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Kendler D, Rootman J, Huber GK, Davies TF. A 64 kDa membrane antigen is a recurrent epitope for natural autoantibodies in patients with Graves’ thyroid and ophthalmic diseases. Clin Endocrinol (Oxf) 1991, 35: 539–47.CrossRefGoogle Scholar
  35. 35.
    Kubota S, Gunji K, Stolarski C, Kennerdell JS, Wall J. Reevaluation of the prevalences of serum autoantibodies reactive with “64-kDa eye muscle proteins” in patients with thyroid-associated ophthalmopathy. Thyroid 1998, 8: 175–9PubMedCrossRefGoogle Scholar
  36. 36.
    Joffe BI, Panz VR, Yamada M, Wall JR. Thyroid-associated ophthalmopathy in black South Africans with Graves’ disease: relationship to serum antibodies reactive against eye muscle and orbital connective tissue autoantigens. Endocrine 2000, 13: 325–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Kubota S, Gunji K, Ackrell BA, et al. The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 1998, 83: 443–7.PubMedGoogle Scholar
  38. 38.
    Gunji K, De Bellis A, Kubota S, et al. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 1999, 84: 1255–62.PubMedGoogle Scholar
  39. 39.
    Hosal BM, Swanson JK, Thompson CR, et al. Significance of serum antibodies reactive with flavoprotein subunit of succinate dehydrogenase in thyroid-associated orbitopathy. Br J Ophthalmol 1999, 83: 605–8.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Kemp EH, Ridgway JN, Smith KA, Watson PF, Weetman AP. Autoantibodies to the flavoprotein subunit of succinate dehydrogenase: analysis of specificity in autoimmune thyroid disease. Clin Endocrinol (Oxf) 2000, 53: 291–9.CrossRefGoogle Scholar
  41. 41.
    Smallman DS, Wall JR. Effects of systemic treatment of Graves’ hyperthyroidism on serum autoantibodies to orbital tissues and thyroid associated ophthalmopathy. Proc Vancouver Orbital Symposium 2002 (in press).Google Scholar
  42. 42.
    Gunji K, Skolnick C, Bednarczuk T. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients. Clin Immunol Immunopathol 1998, 87: 276–81.PubMedCrossRefGoogle Scholar
  43. 43.
    Atabay C, Tyutyunikov A, Scalise D. Serum antibodies reactive with eye muscle membrane antigens are detected in patients with non-specific orbital inflammation. Ophthalmology 1995, 102: 145–53.PubMedCrossRefGoogle Scholar
  44. 44.
    Gunji K, Kubota S, Stolarski C, Wengrowicz S, Kennerdell JS, Wall JR. A 63-kDa skeletal muscle protein associated with eye muscle inflammation in Graves’ disease is identified as the calcium binding protein calsequestrin. Autoimmunity. 1999, 29: 1–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Porter JD, Khanna S, Kaminski HJ, et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile PNAS 98: 12062-12067.Google Scholar
  46. 46.
    Gunji K, Kubota S, Swanson J, et al. Role of the eye muscles in thyroid eye disease: identification of the principal autoantigens. Thyroid 1998, 8: 553–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Dong Q, Ludgate M, Vassart G. Cloning and sequencing of a novel 64-kDa autoantigen recognized by patients with autoimmune thyroid disease. J Clin Endocrinol Metab 1991, 72: 1375–81.PubMedCrossRefGoogle Scholar
  48. 48.
    Boucher A, Bernard N, Zhang ZG, Rodien P, Salvi M, Wall JR. Nature of 64 kDa eye muscle and thyroid membrane proteins and their significance in thyroid-associated ophthalmopathy — an hypothesis. Autoimmunity 1993, 16: 79–82.PubMedCrossRefGoogle Scholar
  49. 49.
    Kromminga A, Hagel C, Arndt R, Schuppert F. Serological reactivity of recombinant 1D autoantigen and its expression in human thyroid and eye muscle tissue: a possible autoantigenic link in Graves’ patients. J Clin Endocrinol Metab 1998, 83: 2817–23.PubMedGoogle Scholar
  50. 50.
    Conley CA, Fowler VM. Localization of the human 64kD autoantigen D1 to myofibrils in a subset of extraocular muscle fibers. Curr Eye Res 1999, 19: 313–22.PubMedCrossRefGoogle Scholar
  51. 51.
    Ross P V, Koenig RJ, Arscott P, et al. Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease. J Clin Endocrinol Metab 1993, 77: 433–8.PubMedGoogle Scholar
  52. 52.
    Zhang ZG, Wall JR, Bernard NF. Tissue distribution and quantitation of a gene expressing a 64-kDa antigen associated with thyroid-associated ophthalmopathy. Clin Immunol Immunopathol 1996, 80: 236–44PubMedCrossRefGoogle Scholar
  53. 53.
    Wall JR, Triller H, Boucher A, Bernard NF, Salvi M, Ludgate M. Antibodies reactive with an intracellular epitope of a recombinant 64-kDa thyroid and eye muscle protein in patients with thyroid autoimmunity and ophthalmopathy. J Endocrinol Invest 1993, 16: 863–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Zhang ZG, Wall JR, Bernard N F. Identification of antigenic epitopes of 1D antigen recognized by antibodies in the serum of patients with thyroid-associated ophthalmopathy. Clin Immunol Immunopathol 1995, 77: 193–200.PubMedCrossRefGoogle Scholar
  55. 55.
    Bernard NF, Nygen TN, Tyutyunikov A, et al. Antibodies against 1D, a recombinant 64-kDa membrane protein, are associated with ophthalmopathy in patients with thyroid autoimmunity. Clin Immunol Immunopathol 1994, 70: 225–33.PubMedCrossRefGoogle Scholar
  56. 56.
    Molnar I, Kaczur V, Boros A, Krajczar G., Balazs C. IgA autoantibodies against human eye muscle antigen detected by western blotting and immunohistochemical methods in Graves’ disease. J Endocrinol Invest 1995, 18: 408–14.PubMedCrossRefGoogle Scholar
  57. 57.
    Tandon N, Yan SL, Arnold K, Metcalfe RA, Weetman A P. Immunoglobulin class and subclass distribution of eye muscle and fibroblast antibodies in patients with thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994, 40: 629–39.CrossRefGoogle Scholar
  58. 58.
    Rosen CE, Raikow RB, Burde RM, Kennerdell JS, Mosseri M, Scalise D. Immunohistochemical evidence for IgA1 involvement in Graves’ ophthalmopathy. Ophthalmology 1992, 99: 146–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Raikow RB, Dalbow MH, Kennerdell JS, et al. Immunohistochemical evidence for IgE involvement in Graves’ orbitopathy. Ophthalmology 1990, 97: 629–35.PubMedCrossRefGoogle Scholar
  60. 60.
    Hiromatsu Y, Fukazawa H, Guinard F, Salvi M, How J, Wall JR. A thyroid cytotoxic antibody that cross-reacts with an eye muscle cell surface antigen may be the cause of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 1988, 67: 565–70.PubMedCrossRefGoogle Scholar
  61. 61.
    Hiromatsu Y, Cadarso L, Salvi M, Wall JR. Significance of cytotoxic eye muscle antibodies in patients with thyroid-associated ophthalmopathy. Autoimmunity 1990, 5: 205–13.PubMedCrossRefGoogle Scholar
  62. 62.
    Barsouk A, Peele KA, Kiljanski J, et al. Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders; close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction. J Endocrinol Invest 1996, 19: 334–31.PubMedCrossRefGoogle Scholar
  63. 63.
    Ludgate ME. Animal models of thyroid-associated ophthalmopathy. Thyroid 2002, 12: 205–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Nagayama Y, Kita-Furuyama M, Ando T, et al. A novel murine model of Graves’ hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J Immunol 2002, 168: 2789–94.PubMedCrossRefGoogle Scholar
  65. 65.
    Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S, Vassart G. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves’ disease. J Clin Invest 2000, 105: 803–11.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Yamada M, Li AW, West KA, Chang C-H, Wall JR. Experimental model for thyroid-associated ophthalmopathy in BALB/c and outbred (CD-1) mice genetically immunized with G2s and the Thyrotropin receptor. Autoimmunity 2002, 35: 403–13.PubMedCrossRefGoogle Scholar
  67. 67.
    Kubota S, Gunji K, Stolarski C, Kennerdell JS, Wall JR. Role of eye muscle antibody measurement in diagnosis of thyroid-associated ophthalmopathy: a laboratory update. Endocr Prac 1998, 4: 127–31.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2004

Authors and Affiliations

  1. 1.Department of Clinical and Biomedical Sciences: Barwon HealthUniversity of Melbourne, The Geelong HospitalGeelongAustralia
  2. 2.University of MilanItaly

Personalised recommendations